Harmony Biosciences Holdings Past Earnings Performance
Past criteria checks 3/6
Harmony Biosciences Holdings has been growing earnings at an average annual rate of 80.7%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 34% per year. Harmony Biosciences Holdings's return on equity is 26.7%, and it has net margins of 22.3%.
Key information
80.7%
Earnings growth rate
98.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 34.0% |
| Return on equity | 26.7% |
| Net Margin | 22.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07
Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Harmony Biosciences: Strong Growth At A Reasonable Price
Mar 04Our First Look At Harmony Biosciences
Nov 04Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations
Aug 17Revenue & Expenses Breakdown
How Harmony Biosciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 618 | 138 | 201 | 85 |
| 31 Dec 23 | 582 | 129 | 193 | 76 |
| 30 Sep 23 | 542 | 151 | 182 | 56 |
| 30 Jun 23 | 499 | 200 | 177 | 79 |
| 31 Mar 23 | 472 | 189 | 172 | 77 |
| 31 Dec 22 | 438 | 181 | 163 | 71 |
| 30 Sep 22 | 401 | 156 | 157 | 68 |
| 30 Jun 22 | 364 | 58 | 148 | 39 |
| 31 Mar 22 | 331 | 49 | 137 | 33 |
| 31 Dec 21 | 305 | 35 | 132 | 30 |
| 30 Sep 21 | 271 | 12 | 126 | 31 |
| 30 Jun 21 | 235 | 17 | 115 | 23 |
| 31 Mar 21 | 200 | -7 | 103 | 21 |
| 31 Dec 20 | 160 | -64 | 96 | 19 |
| 30 Sep 20 | 109 | -110 | 92 | 19 |
| 30 Jun 20 | 64 | -146 | 94 | 19 |
| 31 Mar 20 | 26 | -165 | 90 | 20 |
| 31 Dec 19 | 6 | -187 | 81 | 70 |
Quality Earnings: HRMY has high quality earnings.
Growing Profit Margin: HRMY's current net profit margins (22.3%) are lower than last year (40.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HRMY has become profitable over the past 5 years, growing earnings by 80.7% per year.
Accelerating Growth: HRMY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HRMY had negative earnings growth (-27.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (15.5%).
Return on Equity
High ROE: HRMY's Return on Equity (26.7%) is considered high.